{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Huang L"],"funding":["Natural Science Foundation of Guangxi Province","Middle-aged and Young Teachers&apos; Basic Ability Promotion Project of Guangxi","The State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources"],"pagination":["18008-18015"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9053630"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(31)"],"pubmed_abstract":["A series of novel dehydroabietic acid derivatives containing pyrimidine moieties were designed and synthesized to explore more efficacious and less toxic antitumor agents according to the principle of combination and hybridization. The cytotoxicity against human liver cancer (HepG2) cells, human breast cancer (MCF-7) cells, human colon cancer (HCT-116) cells, human lung cancer (A549) cells, and human normal liver cells (LO2) was estimated by MTT assay <i>in vitro</i>. Cytotoxic activity screening revealed that most of the compounds showed moderate to high levels of cytotoxicity against these four cancer cell lines and that some displayed more potent inhibitory activities compared with 5-FU. In particular, compound 3b exhibited promising cytotoxicity with IC<sub>50</sub> values ranging from"],"journal":["RSC advances"],"pubmed_title":["Synthesis and biological evaluation of dehydroabietic acid-pyrimidine hybrids as antitumor agents."],"pmcid":["PMC9053630"],"funding_grant_id":["CMEMR2019-B02","2019KY0551","2018GXNSFAA281200","2018GXNSFAA138165"],"pubmed_authors":["Huang G","Li F","Ma X","Li A","Li Q","Huang L","Huang R","Zhou X","Pang F"],"additional_accession":[]},"is_claimable":false,"name":"Synthesis and biological evaluation of dehydroabietic acid-pyrimidine hybrids as antitumor agents.","description":"A series of novel dehydroabietic acid derivatives containing pyrimidine moieties were designed and synthesized to explore more efficacious and less toxic antitumor agents according to the principle of combination and hybridization. The cytotoxicity against human liver cancer (HepG2) cells, human breast cancer (MCF-7) cells, human colon cancer (HCT-116) cells, human lung cancer (A549) cells, and human normal liver cells (LO2) was estimated by MTT assay <i>in vitro</i>. Cytotoxic activity screening revealed that most of the compounds showed moderate to high levels of cytotoxicity against these four cancer cell lines and that some displayed more potent inhibitory activities compared with 5-FU. In particular, compound 3b exhibited promising cytotoxicity with IC<sub>50</sub> values ranging from","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 May","modification":"2025-04-22T01:43:50.83Z","creation":"2025-04-05T20:03:14.511Z"},"accession":"S-EPMC9053630","cross_references":{"pubmed":["35517208"],"doi":["10.1039/d0ra02432e"]}}